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Delays in seeking and accessing treatment for rifampicin-resistant tuberculosis (RR-TB)
and multi-drug resistant (MDR-TB) are major impediments to TB control in high-burden,
resource-limited settings.
Method
We prospectively determined health-seeking behavioural patterns and associations with
treatment outcomes and costs among 68 RR-TB patients attending conveniently selected
facilities in a decentralised system in Harare, Zimbabwe.
Results
From initial symptoms to initiation of effective treatment, patients made a median number of
three health care visits (IQR 2–4 visits) at a median cost of 13% (IQR 6–31%) of their total
annual household income (mean cost, US$410). Cumulatively, RR-TB patients most fre-
quently first visited private facilities, i.e., private pharmacies (30%) and other private health
care providers (24%) combined. Median patient delay was 26 days (IQR 14–42 days);
median health system delay was 97 days (IQR 30–215 days) and median total delay from
symptom onset to initiation of effective treatment was 132 days (IQR 51–287 days). The
majority of patients (88%) attributed initial delay in seeking care to “not feeling sick enough.”
Total delay, total cost and number of health care visits were not associated with treatment or
clinical outcomes, though our study was not adequately powered for these determinations.
PLOS ONE







Citation: Tadokera R, Huo S, Theron G, Timire C,
Manyau-Makumbirofa S, Metcalfe JZ (2021) Health
care seeking patterns of rifampicin-resistant
tuberculosis patients in Harare, Zimbabwe: A
prospective cohort study. PLoS ONE 16(7):
e0254204. https://doi.org/10.1371/journal.
pone.0254204
Editor: Anna Maria Mandalakas, Baylor College of
Medicine, UNITED STATES
Received: May 10, 2020
Accepted: June 22, 2021
Published: July 16, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0254204
Copyright: © 2021 Tadokera et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting information
files (file name: Anonymized Study Data).
Conclusions
Despite the public availability of rapid molecular TB tests, patients experienced significant
delays and high costs in accessing RR-TB treatment. Active case finding, integration of pri-
vate health care providers and enhanced service delivery may reduce treatment delay and
TB associated costs.
Introduction
Multi-drug resistant (MDR) tuberculosis (TB) remains a public health crisis and health secu-
rity threat [1]. The social and economic burden associated with TB and MDR-TB treatment
[2], compounded by the HIV epidemic, places a disproportionate burden of disease on Sub-
Saharan African countries [3, 4]. TB diagnosis, treatment, and prevention are strongly associ-
ated with socio-economic and behavioural factors [5–7]. Operational challenges related to
weak, poorly resourced health systems are a barrier to TB prevention and control activities.
For MDR-TB, timing delays can significantly determine treatment outcomes and are likely to
increase the infectiousness and disease transmission in a community [4]. The resultant delays
to diagnosis and effective treatment related to health system weaknesses are further informed
by patient choices and behaviour [8]. Ultimately, such delays increase community transmis-
sion and may worsen treatment outcomes [9].
Despite the availability of free TB treatment in the public sector and the goal of universal
health coverage (UHC) [10], the economic consequences for families affected by TB are often
severe [11]. These include direct medical costs, direct non-medical costs and income loss
(resulting from indirect or opportunity costs) [12]. The World Health Organization (WHO)
defines TB-associated health care expenditures above a certain proportion (typically 20%) of
available annual income as “catastrophic”, though the specific threshold is expected to vary by
setting and circumstances [13, 14]. Resulting impoverishment may be high in settings such as
Zimbabwe, where 85% of the total workforce is employed within the informal sector [15].
RR-TB has conventionally been used as a reliable proxy for MDR-TB, particularly in
resource limited settings [16]. We conducted a prospective cohort study to understand health-
care seeking behaviour, healthcare expenditures, and associations with treatment outcome
(24-month survival) among RR-TB patients starting treatment in conveniently selected out-
patient facilities in Harare, Zimbabwe.
Materials and methods
Study population
RR-TB patients initially seeking health care within the Harare Metropolitan area between
November 2011 and November 2012 were recruited from eight conveniently selected health
facilities. Detailed enrolment and diagnosis criteria have previously been described [17].
Briefly, persons who had a history of prior TB treatment or were suspected of having drug-
resistant pulmonary TB were recruited into a prospective cohort study. Presumptive drug-
resistant TB patients were identified as symptomatic patients presenting with a history of> =
1 month of prior TB treatment (relapse, treatment after loss to follow up or treatment failure),
contact with a person with known or possible drug-resistant TB; or with a rifampicin-resistant
result on Xpert MTB/RIF. RR-TB diagnosis was confirmed by molecular TB assay and/or phe-
notypic drug susceptibility testing. At the time our study was undertaken, a partially
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decentralized MDR-TB/RR-TB treatment system was in place in Harare. Patients could only
be diagnosed and recommended for treatment via a central MDR-TB clinic (i.e., at Wilkins
Hospital) based in Harare, but MDR-TB/RR-TB treatment could be dispensed through
peripheral, local health clinics. We estimated that approximately 60% of the population base
was likely included in our sample [17].
Data collection
Data were collected using a mixed methods approach via an open-ended healthcare-seeking
behaviour questionnaire designed to capture both quantitative and qualitative responses
through in-depth patient interviews. The open-ended questionnaire allowed respondents to
provide detailed responses on their health-seeking pathways and reasons for delay in seeking
care. A trained research nurse administered the questionnaire. Quantitative data included
basic socio-demographic information. Health-seeking behaviour included type of facilities or
health care provider from which treatment was first sought; delays in seeking health care; rea-
sons for delays; and direct and indirect costs incurred. Additional variables included whether
patients had been referred from outside Harare, HIV and antiretroviral treatment status, TB
treatment history and TB symptoms. Final clinical outcome was defined as 24-month patient
survival, ascertained through review of medical records and contact with next-of-kin. Data
were electronically captured in Research Electronic Data Capture tools (REDCap) [18] hosted
at the University of California, San Francisco.
Definitions
Patient delay was defined as the time from onset of disease-associated symptoms to first health
care visit. Health system delay was defined as the time from first medical facility visit to initia-
tion of effective RR-TB treatment. Total delay was defined as the sum of patient and health sys-
tem delays and included both diagnostic delay and repeat visits before initiation of treatment.
Direct costs were those directly associated with health care such as diagnostic tests, doctors’
fees or medication costs. Indirect costs included travel, lodging or food expenses indirectly
associated with health care seeking. Total costs were defined as the sum of direct and indirect
costs incurred by a patient accessing care. A polyclinic was defined as a patient’s local govern-
ment clinic (usually the first point of contact in this setting). Informal employment was
defined as engagement in an economic activity that is not taxed or formally registered. Final
clinical outcome was defined as 24-month patient survival.
Statistical analysis
Statistical analysis was performed using Stata Version 13 (StataCorp, College Station, TX,
USA) and R software (version 3.5.3). Descriptive statistics for numeric variables (such as age
or income) were computed and are reported as median and interquartile range (IQR). Chi-
square tests were used to compute associations between continuous and categorical variables.
We used the Kruskal Wallis test to analyse the associations between health care facility first
attended; delays (patient and total time delays) and cost (both first visit and total costs
incurred) to patients. Mann Whitney tests were used to compute associations between delay
and clinical outcomes. Results are reported as medians, IQRs or proportions.
Both simple and multiple linear regression analyses were used to assess the associations
between delay and explanatory variables. Potential risk factors for delay and variables associ-
ated with delay in the bivariate analysis (P�0.2) were included in a final multiple linear regres-
sion model. A p-value of less than 0.05 was considered statistically significant. R software
(version 3.5.3) was used to compute the visual pathways of care. Thematic analysis was used to
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identify and analyse patterns and trends within the qualitative data gathered from the open-
ended questionnaires [19].
Ethical approval
The Medical Research Council of Zimbabwe (MRCZ/A1552), and the Institutional Review
Board of Biomedical Research and Training Institute, and Human Research Protection Pro-
gramme, University of California, San Francisco (USCF) provided ethical approval (10–
05115). All participants gave written informed consent before enrolling in the study.
Results
Study participants
Of 139 participants with RR-TB in the main study, 73 (53%) agreed to participate in the
health-seeking behaviour (HSB) survey (Fig 1). A final sample of 68 participants with follow-
up data was included in the final analysis: five participants were lost to follow up during the
study period and were excluded from further analysis. More than 70% (48/68) of study partici-
pants were female, mainly from the economically active age group (median 34 years, IQR 29–
42 years); with more than 73%, (50/68) educated up to secondary level (Table 1). Forty-five
percent (30/67) of participants were employed in the informal sector; median monthly income
was US$175 (IQR US$100-$300). Two-thirds of the sample (43/68) were HIV-positive, among
whom 31 (73.8%) were on antiretroviral therapy. Overall, 37 (55.2%) of participants presented
with new RR-TB, while other participants had experienced from one to three prior TB epi-
sodes (29.9% and 3.0% respectively).
Time delays and costs associated with health care visits
Patients delayed seeking care by a median of 26 days (IQR 14–42 days) from onset of TB symp-
toms (Table 2). Median health system delay (i.e., time from first health care visit to initiation
of effective RR-TB treatment) was 97 days (IQR 30–215 days). Health system delay was longest
when the first point of contact was government polyclinics (median 150 days, IQR 18–300
days), followed by private clinics (median 102 days, IQR 30–154 days) and pharmacies
(median 97 days, IQR 67–210 days). Median total delay (i.e., patient plus health system delay)
was 132 days (IQR 51–287 days). Total delay was longest when a polyclinic was the first health
system contact (median, 221 days, IQR 45–338 days). Costs associated with first visit were
highest for private clinics (median US$30, IQR $14–45 days) and lowest for polyclinics
(median $US0, IQR $0–4), across facilities visited (p<0.001). Cumulative costs were highest
for participants who first visited a pharmacy (median US$45, IQR $19–80) and private clinics/
hospital (median US$40, IQR $15–56), but least for those first visiting government polyclinics
(median US$8, IQR $5–16). Overall, a median of 13% (IQR 6–31%) of total annual household
income, (equivalent to a mean cost of US$410), was spent on seeking RR-TB health care. At
least 30% (23/68) households incurred TB related costs which can be considered as cata-
strophic i.e., above 20% of annual household income.
Reasons for delays in seeking care
Most study participants (n = 59/68, 88%) who delayed seeking care for their first health care
visit reported not feeling sick enough to warrant a visit to the clinic or thinking that they had a
minor cough, which could be treated using over-the-counter remedies. Participants who did
not first seek care at primary care facilities (polyclinics) reported anticipating longer waiting
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times; inadequate testing facilities or poor service at the clinic as reasons for not first seeking
care at the clinic.
Pathways to care and health-seeking visits
Based on qualitative interviews conducted among patients, urban residents preferred to visit
pharmacies and supermarkets for home-based and over-the-counter remedies before visiting
polyclinics or primary care facilities. When the care received was inadequate or symptoms
were not improving, these patients would later attend government administered clinics and be
referred to TB-referral clinics. Rural patients from outside Harare had a different typical care
pathway characterised by home-based care, attendance at a rural hospital or clinic, followed by
referral to a RR-TB treatment facility in Harare (Fig 2).
Healthcare facilities attended
Health-seeking behaviour among study participants was cyclic, with participants making up to
six visits (median, three visits) before initiating RR-TB treatment. Repeat visits at the same
health facility were more common for polyclinics and private healthcare facilities. For their
first visit, most participants attended a polyclinic (37%) followed by a pharmacy (30%), and
private health care providers (24%) (Fig 2). Cumulatively, for the total 215 health care visits
recorded in the study, nearly half (n = 90/215, 42%) were at the polyclinic with participants
making up to five polyclinic visits (Fig 3).
Association of total delay with clinical outcomes
We found that after adjusting for age and gender, living with HIV and being employed were
associated with shorter total delay, (p = 0.11, median 98 days and p = 0.25, median 104 days
respectively), and TB retreatment was likely to be associated with a longer delay (p = 0.20). We
found no significant associations with mortality and median total delay or total cost incurred
Fig 1. Participant flowchart (n = 68).
https://doi.org/10.1371/journal.pone.0254204.g001
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(Table 3). However, our sample size limited our ability to make conclusive determinations
about the associations between delay and the risk factors that were assessed.
Discussion
Our study demonstrates that substantial delays in both seeking and accessing care for persons
with confirmed RR-TB are common. Overall delay was highest among patients first attending
government polyclinics, with a median of seven months (221 days) from onset of symptoms to
effective treatment. Most participants first sought care at private health care facilities outside
of the national TB program, citing long waiting periods, mistrust and inadequate facilities and
services as barriers to accessing public sector care. Patient costs averaged approximately 13%
of monthly income with at least 30% of the households incurring costs that may be considered
“catastrophic”.
Our study showed community delays to effective rifampicin-resistant TB treatment despite
the availability of molecular TB diagnostics such as Xpert. These findings are in agreement
Table 1. Socio-demographic and clinical characteristics of RR-TB patients, Harare, Zimbabwe.
Variable Name Total sample (N = 68)
Female, n (%) 48 (70.6)
Age, years, median (IQR) 34 (29–42)
Referred from outside Harare, n (%) 12 (19.4)




Occupation�, n = 67




Monthly income, $US, median (IQR) 175 (100–300)
HIV positive, n (%) 43 (65.2)
On ART 31 (73.8)
TB history
New TB 37 (55.2)
Retreatment TB 30 (44.8)





TB symptoms at presentation, n (%)
Cough 68 (100)
Fever 45 (66.2)
Weight loss 54 (79.4)
Night sweats 48 70.6)
49
�Missing Information: HIV status, n = 2; Education, n = 1; Occupation, n = 1; TB history, n = 1; Prior TB incidents,
n = 1.
https://doi.org/10.1371/journal.pone.0254204.t001
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with studies from this era that have documented similar delays in accessing care. Total treat-
ment delay among TB patients were shown to be 126 days in an urban study [20]; 70 days in a
rural study [21] and up to 170 days in a rural study [22] in three South African TB studies.
Although our study was in an urban setting and among RR-TB patients, we observed patterns
of prolonged delays averaging 97 days (overall) for health system, and as high as 150 days for
polyclinics. While for the South African studies delays to treatment initiation were mainly
attributed to late presentation, [21, 22] in our study, delays were largely health system related.
In contrast, a systematic review on 23 studies from India reported shorter average patient
delays of 18.4 days and total delays of 55 days from when symptomatic patients with active TB
first contacted a health care provider [23]. Differences between the Indian studies and our
findings could be attributed to the health care system setting in the different countries. Across
a number of other studies, delays in treatment initiation were mainly attributed to a combina-
tion of diagnostic delays and late presentation for care [23–26]. Prolonged diagnostic and





Health system delay days,
median (IQR)
Total delay days, median
(IQR)
First visit cost $US,
median (IQR)
Total cost $US, median
(IQR)
Pharmacy 21 (14–26) 97 (67–210) 116 (88–247) 10 (5–18) 45 (19–80)
Government
polyclinic
30 (14–60) 150 (18–300) 221 (45–338) 0 (0–4) 8 (5–16)
Centralised RR-TB
clinic
18 (14–38) 56 (33–163) 58 (21–81) 6 (5–13) 26 (5–40)
Private clinic 30 (18–70) 102 (30–154) 139 (45–226) 30 (14–45) 40 (15–56)
Other† 30 (21–30) 52 (9–248) 105 (56–278) 8 (1–14) 14 (6–21)
Overall 26 (14–42) 97 (30–215) 132 (51–287) 6 (2–16) 23 (10–55)
p-value 0.084 0.786 0.586 <0.001 0.004
†HIV testing clinic (n = 1), herbalist (n = 1), project clinic (n = 1), grocery shop (n = 2), missing (n = 1).
https://doi.org/10.1371/journal.pone.0254204.t002
Fig 2. Cyclic care-seeking pathways and repetitive visits followed by study participants. Different colours
correspond to the health facility where patients sought care. The different arrows represent successive care-seeking
visits as shown in the figure key.
https://doi.org/10.1371/journal.pone.0254204.g002
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treatment initiation delays pose serious challenges as TB treatment may only be initiated after
disease has progressed, potentially worsening prognosis and treatment outcomes [27, 28].
Indirect costs remain a deterrent to seeking health care for many patients, despite TB treat-
ment being nominally free in government facilities in most countries [11, 29, 30]. Loss of
income due to time taken when sick or to seek treatment is a major issue and an indirect
expense particularly when employment is informal or seasonal. The majority of our study par-
ticipants who delayed seeking treatment were informally employed with limited safety nets. It
is of concern that many patients visited private health care facilities or pharmacies as their first
point contact, incurring additional expenses in the process. Our findings corroborate studies
in other settings where patients incurred higher costs and a circuitous path to care, [24] result-
ing in significant delays in accessing treatment [31]. The economic burden of TB treatment
remains considerable, especially in poorer and developing countries without universal health
coverage (UHC), including our study setting [5, 32]. For many, the cost of accessing care can
Fig 3. Different Health care facilities attended by study participants and the proportion (%) of participants
attending each facility as a proportion of all health care visits for each health care visit (Visit 1–6). Different
colours correspond to the health facility where patients sought care while different arrows represent successive care-
seeking visits. �Four patients were admitted to hospital on first contact with the health system and are not included in
this figure.
https://doi.org/10.1371/journal.pone.0254204.g003
Table 3. Association between delay, cost and 24-month survival.
Died (n = 6) Survived (n = 62) p-value�
Total delay (days) 168.5 (83.3–309.25) 132.0 (49.8–280.8) 0.77
Patient delay (days) 30 (23.3–30) 21 (14–42) 0.62
Total cost (dollars, US) 24.5 (8–40.3) 21.5 (10.3–55.5) 0.75
�Mann-Whitney test.
https://doi.org/10.1371/journal.pone.0254204.t003
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push already poor families to the brink of poverty. Furthermore, as we have shown, repeat vis-
its in care-seeking pathways increased cumulative costs and delayed diagnosis and treatment
initiation. Studies from India, Indonesia, Thailand, South Africa and other similar settings
have shown that the cost of TB can be catastrophic especially for low-income households [6,
12, 32–35]. According to WHO, catastrophic costs are incurred when patients spend a consid-
erable proportion of their annual income on both direct and indirect medical costs [34]. Other
unaccounted (indirect) costs for TB may include income loss due to seeking treatment and
loss of productivity due to illness or when household members assume carer roles for a bedrid-
den TB patient. The financial burden of TB is evident from the low average income per house-
hold and proportion of costs (up to a maximum of 31% of annual household income) incurred
on TB-treatment costs reported by participants in this study. Up to 30% of households report-
edly spent more than 20% of annual household income on TB related costs, a threshold which
has been previously described as catastrophic [12].
In 2016, the WHO issued revised guidance recommending MDR-TB treatment for all
RR-TB patients regardless of confirmatory resistance testing as well as the use of line probe
assays for drug sensitivity testing [36]. At the time of our study, MDR-TB diagnosis was done
by culture, and drug susceptibility testing was done to confirm isoniazid resistance at a central
reference laboratory (although many patients would be treated on the basis of rifampicin resis-
tant test), increasing delays to treatment initiation. Our findings point to a need to improve
public sector care services to ensure that they are the preferred first contact for TB patients and
that patients access treatment promptly once they enter the care cascade. This is particularly
pertinent given the protracted delay in initiating treatment by patients attending polyclinics
that we report in this study. Increased case-finding and educational campaigns would assist in
reducing patient-associated delays in seeking care. Furthermore, supportive social protection
policies and interventions such as UHC [37] in resource-constrained settings could ensure
that TB patients are not deterred from seeking care by exorbitant out-of-pocket costs which
may exert financial burden on impoverished families [12, 33]. Our findings corroborate previ-
ous studies from other TB burdened settings that showed that consulting private health care
providers aggravate delays in TB treatment access as they are not equipped to promptly diag-
nose and initiate TB treatment [24, 26, 38, 39]. Private-public health partnerships could facili-
tate prompt TB diagnosis, reduce high costs and reduce treatment delays among presumptive
MDR-TB and TB patients as has been previously reported in other studies [40–42]. Taken
together, these findings point to a need for interventions including quality improvement (par-
ticularly in the public healthcare system), to reduce delays in MDR-TB and RR-TB patient
diagnosis and ensure prompt treatment once patients make contact with a health care facility.
We acknowledge a few limitations in our study. First, we conducted this study within a pro-
spective cohort of RR-TB patients who underwent extensive diagnostic testing at time of refer-
ral for RR-T testing and treatment; true programmatic delays may be longer. Second, our
study was underpowered to determine associations between clinical outcomes and health-
seeking behaviour-related delays. Third, female participants were over-represented in our
study, [17] indicating a possible selection bias. Furthermore, data was self-reported and so
may be subject to self-report bias.
In conclusion, we found significant delays in accessing TB care in this setting, particularly
in the public health sector. The majority of patients preferred private care providers as their
first contact, resulting in cyclical care-seeking pathways, significant delays and additional
health-care costs, which did not correlate with prompt access to care. As pharmacies are the
first point of contact for many patients, we recommend that pharmacists and other private
health care providers should be trained in appropriate TB screening and referral of potential
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11. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients
in low-and middle-income countries: a systematic review. European Respiratory Journal. 2014;
43(6):1763–75. https://doi.org/10.1183/09031936.00193413 PMID: 24525439
12. Wingfield T, Boccia D, Tovar M, Gavino A, Zevallos K, Montoya R, et al. Defining catastrophic costs and
comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective
cohort study, Peru. PLoS medicine. 2014; 11(7):e1001675. https://doi.org/10.1371/journal.pmed.
1001675 PMID: 25025331
13. Chuma J, Gilson L, Molyneux C. Treatment-seeking behaviour, cost burdens and coping strategies
among rural and urban households in Coastal Kenya: an equity analysis. Tropical Medicine & Interna-
tional Health. 2007; 12(5):673–86. https://doi.org/10.1111/j.1365-3156.2007.01825.x PMID:
17445135
14. Fochsen G. Health care seeking among individuals with cough and tuberculosis: a population-based
study from rural India. The international journal of tuberculosis and lung disease: the official journal of
the International Union against Tuberculosis and Lung Disease. 2006; 10(9):995. PMID: 16964790
15. Kedem S. Zimbabwe’s informal economy demands recognition amid devastating Covid-19 response.
African Business. 2020.
16. Timire C, Metcalfe JZ, Chirenda J, Scholten JN, Manyame-Murwira B, Ngwenya M, et al. Prevalence of
drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey. International
Journal of Infectious Diseases. 2019; 87:119–25. https://doi.org/10.1016/j.ijid.2019.07.021 PMID:
31357057
17. Metcalfe JZ, Makumbirofa S, Makamure B, Sandy C, Bara W, Mungofa S, et al. Drug-resistant tubercu-
losis in high-risk groups, Zimbabwe. Emerg Infect Dis. 2014; 20(1):135–7. https://doi.org/10.3201/
eid2001.130732 PMID: 24377879
18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture
(REDCap)—a metadata-driven methodology and workflow process for providing translational research
informatics support. Journal of biomedical informatics. 2009; 42(2):377–81. https://doi.org/10.1016/j.jbi.
2008.08.010 PMID: 18929686
19. Clarke V, Braun V. Teaching thematic analysis: Overcoming challenges and developing strategies for
effective learning. The psychologist. 2013; 26(2).
20. Lewis K, Stephens C, Shahidi M, Packe G. Delay in starting treatment for tuberculosis in east London.
Communicable disease and public health. 2003; 6(2):133–8. PMID: 12889293
21. Pronyk P. Assessing health seeking behaviour among tuberculosis patients in rural South Africa. The
international journal of tuberculosis and lung disease: the official journal of the International Union
against Tuberculosis and Lung Disease. 2001; 5(7):619. PMID: 11467368
22. Boniface R, Moshabela M, Zulliger R, MacPherson P, Nyasulu P. Correlates of delayed diagnosis
among human immunodeficiency virus-infected pulmonary tuberculosis suspects in a rural HIV clinic,
South Africa. Tuberculosis research and treatment. 2012; 2012.
23. Sreeramareddy CT, Qin ZZ, Satyanarayana S, Subbaraman R, Pai M. Delays in diagnosis and treat-
ment of pulmonary tuberculosis in India: a systematic review. The International Journal of Tuberculosis
and Lung Disease. 2014; 18(3):255–66. https://doi.org/10.5588/ijtld.13.0585 PMID: 24670558
24. Skordis-Worrall J, Hanson K, Mills A. Confusion, caring and tuberculosis diagnostic delay in Cape
Town, South Africa. The international journal of tuberculosis and lung disease. 2010; 14(2):171–80.
PMID: 20074408
25. Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary
tuberculosis: a systematic review of literature. BMC infectious diseases. 2009; 9(1):1–10. https://doi.
org/10.1186/1471-2334-9-91 PMID: 19519917
26. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculo-
sis. BMC public health. 2008; 8(1):1–9. https://doi.org/10.1186/1471-2458-8-15 PMID: 18194573
PLOS ONE RR-TB patients’ health-seeking behaviour
PLOS ONE | https://doi.org/10.1371/journal.pone.0254204 July 16, 2021 11 / 12
27. Takarinda KC, Harries AD, Nyathi B, Ngwenya M, Mutasa-Apollo T, Sandy C. Tuberculosis treatment
delays and associated factors within the Zimbabwe national tuberculosis programme. BMC public
health. 2015; 15(1):29. https://doi.org/10.1186/s12889-015-1437-7 PMID: 25631667
28. Thorson A. Health-seeking behaviour of individuals with a cough of more than 3 weeks. The Lan-
cet2000. p. 1823. https://doi.org/10.1016/s0140-6736(00)03241-4 PMID: 11117921
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